Von Willebrand Factor And Coagulation Factor VIII (Human)
Pronunciation: (WILL-ate).
- Generic name
- von Willebrand factor and coagulation factor VIII (human)
- Brand names
- VWF8, FactorWil, Wilate
- Drug class
- Cardiovascular & Circulatory System
Availability and supply rules vary by country
Trade names by country: United Kingdom
Australia: · Full directory
What von Willebrand factor and coagulation factor VIII (human) is and how it works
Uses, formulations, monitoring, and supply rules can differ by patient, product, and country. Follow the exact local product information and professional advice.
Mechanism of action: how von Willebrand factor and coagulation factor VIII (human) works
Wilate provides exogenous von Willebrand factor (VWF) and coagulation factor VIII (FVIII), both derived from human plasma. VWF mediates platelet adhesion to sites of vascular injury and stabilizes circulating FVIII, which is essential for the intrinsic pathway of blood coagulation. By replacing deficient or dysfunctional VWF and FVIII, Wilate restores hemostasis in patients with von Willebrand disease and hemophilia A. (1)
What von Willebrand factor and coagulation factor VIII (human) is used for
Treatment of hemorrhage in von Willebrand disease (VWD)
Treatment of hemorrhage in von Willebrand disease (VWD) (1)
Prevention of hemorrhage in von Willebrand disease (VWD) during surgery or invasive procedures
Prevention of hemorrhage in von Willebrand disease (VWD) during surgery or invasive procedures (1)
Treatment of hemorrhage in hemophilia A
Treatment of hemorrhage in hemophilia A (1)
Prevention of hemorrhage in hemophilia A during surgery or invasive procedures
Prevention of hemorrhage in hemophilia A during surgery or invasive procedures (1)
Before taking von Willebrand factor and coagulation factor VIII (human)
Do not take / not appropriate for
- Contraindicated in patients with known hypersensitivity to VWF, FVIII, or any excipients. (Contraindication) (1)
- Risk of transmission of infectious agents, though minimized by screening and viral inactivation steps. (Contraindication) (1)
Tell your clinician about
(1)How to take von Willebrand factor and coagulation factor VIII (human)
- General Instructions: Wilate is administered as an intravenous infusion. Always use as directed by your healthcare provider.. Adult Dosing: Dosing is individualized based on the severity of bleeding, body weight, and clinical response. Typical doses for VWD range from 20–80 IU/kg for minor to major bleeding episodes.. Pediatric Dosing: Children are dosed based on body weight and clinical need. Pediatric dosing is similar to adults but must be carefully calculated by a healthcare provider.. Administration: Wilate is reconstituted with sterile water and infused slowly into a vein. Administration should be performed by a trained professional or by the patient/caregiver after proper training.. When To Stop: Continue treatment as prescribed. Do not stop without consulting your doctor, even if you feel better.. Storage: Store Wilate in the refrigerator (2°C–8°C/36°F–46°F). Do not freeze. Protect from light. Once reconstituted, use immediately or within the time specified by the manufacturer.
- This page does not provide a dose calculator. Dosing must follow the prescriber, pharmacist, or product label.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)
Missed dose
If you miss a dose, contact your healthcare provider for instructions. Do not take an extra dose to make up for a missed one.
Overdose
In case of overdose, seek immediate medical attention. Overdose may increase the risk of blood clots and other serious complications. Supportive care and monitoring are essential. (1)
Side effects
Side effects and their urgency vary; report severe, persistent, or concerning symptoms to a healthcare professional.
Headache
Incidence: Reported in the clinician-authored database; frequency not established
Dizziness
Incidence: Reported in the clinician-authored database; frequency not established
Nausea
Incidence: Reported in the clinician-authored database; frequency not established
Allergic reactions (rash, itching, swelling)
Incidence: Reported in the clinician-authored database; frequency not established
Thromboembolic events (blood clots)
Incidence: Reported in the clinician-authored database; frequency not established
Development of inhibitors to von Willebrand factor or factor VIII
Incidence: Reported in the clinician-authored database; frequency not established
Fever
Incidence: Reported in the clinician-authored database; frequency not established
Serious warnings
Risk of allergic reactions, including anaphylaxis — serious
Symptoms: Risk of allergic reactions, including anaphylaxis. Potential for thromboembolic events (blood clots). Development of inhibitors (antibodies) to factor VIII or VWF. Transmission of infectious agents cannot be completely ruled out. Use with caution in patients with a history of cardiovascular disease.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (1)
Contraindications recorded in the clinician database — serious
Symptoms: Contraindications recorded in the clinician database: Contraindicated in patients with known hypersensitivity to VWF, FVIII, or any excipients. Use with caution in patients with a history of thromboembolic events, cardiovascular disease, or known inhibitors to VWF or FVIII. Monitor for allergic reactions and signs of thrombosis. Risk of transmission of infectious agents, though minimized by screening and viral inactivation steps.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (1)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Recorded interactions | Wilate may interact with other blood products or medications that affect clotting. Inform your doctor about all medicines, supplements, and herbal products you are taking. No significant drug-drug interactions have been reported, but caution is advised with antifibrinolytics and other pro-coagulant agents. | (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Pregnancy
There are no data on Wilate use in pregnant women to inform a drug-associated risk, and animal reproduction studies have not been conducted with Wilate. Because von Willebrand disease and hemophilia A themselves carry bleeding risks around childbirth, use during pregnancy is a decision for the clinician managing the pregnancy together with a hematologist, weighing the bleeding-disorder risk against the lack of safety data for the product itself. (1)
Breastfeeding
There is no information on whether Wilate passes into human breast milk, its effect on a breastfed infant, or its effect on milk production. Discuss feeding options with the clinician managing your care. (1)
Children
CORRECTED — an earlier draft of this field said safety was not established in children under 12, which only reflects the hemophilia A indication. The FDA label indication is broader: for von Willebrand disease, Wilate is approved in adult AND pediatric patients (no lower age restriction stated) for on-demand treatment, perioperative management, and routine prophylaxis. For hemophilia A specifically, Wilate is approved in adult and pediatric patients 12 years of age and older only; safety and effectiveness have not been established for hemophilia A patients under 12. Dosing in children uses the same weight-based VWF/FVIII activity targets as adults (initial dose of 40-60 IU/kg VWF activity and 20-30 IU/kg FVIII activity), individualized to clinical response and laboratory monitoring, typically dosed every 12-24 hours; maximum daily/single dose is not fixed. (1)
Renal_impairment
The FDA label has no dedicated section on kidney or liver impairment for Wilate. As a plasma-derived replacement protein rather than a small-molecule drug, it is not cleared by the kidneys or liver in the usual sense, and dosing is instead guided by bleeding severity, body weight, and blood test monitoring of clotting-factor activity rather than by kidney or liver function tests. Still, tell the clinician managing your treatment about any significant kidney or liver disease, since it can affect overall bleeding risk and monitoring. (1)
Hepatic_impairment
The FDA label has no dedicated section on kidney or liver impairment for Wilate. As a plasma-derived replacement protein rather than a small-molecule drug, it is not cleared by the kidneys or liver in the usual sense, and dosing is instead guided by bleeding severity, body weight, and blood test monitoring of clotting-factor activity rather than by kidney or liver function tests. Still, tell the clinician managing your treatment about any significant kidney or liver disease, since it can affect overall bleeding risk and monitoring. (1)
Monitoring
(1)Storage
Store for up to 36 months at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light, from the date of manufacture. Within that period, Wilate may instead be stored for up to 6 months at room temperature (maximum 25°C/77°F). Do not freeze. Once reconstituted, use promptly per the manufacturer's instructions.
Professional information
Clinician-facing context only. This section does not replace current product labeling.
General
Indication: Treatment of hemorrhage in von Willebrand disease (VWD)
Dose summary: Initial dose of 40-60 IU/kg of von Willebrand factor (VWF) activity and 20-30 IU/kg of factor VIII (FVIII) activity.
Renal context: The FDA label has no dedicated renal-impairment or hepatic-impairment dosing section for Wilate — as a plasma-derived replacement protein (von Willebrand factor and factor VIII) given by IV infusion, it is not cleared through the kidneys or liver the way small-molecule drugs are, and dosing is instead individualized based on the severity of bleeding, body weight, and clinical/laboratory response (target VWF and FVIII activity levels), regardless of kidney or liver function. There is no published renal- or hepatic-impairment dose-adjustment table for this reason, not because of an oversight. (1)
Frequently asked questions
What conditions does Wilate treat?
Wilate is used to treat and prevent bleeding in people with von Willebrand disease (VWD) and hemophilia A.
How is Wilate administered?
Wilate is given as an intravenous infusion, usually by a healthcare professional or by the patient/caregiver after proper training.
Can Wilate be used during pregnancy or breastfeeding?
Wilate should be used during pregnancy or breastfeeding only if clearly needed and prescribed by your doctor. Discuss risks and benefits with your healthcare provider.
What should I do if I have an allergic reaction to Wilate?
If you experience symptoms such as swelling, difficulty breathing, or hives during the infusion, this can be a sign of a serious allergic reaction — seek emergency medical attention immediately (call emergency services), and if you are self-infusing, your training from your healthcare provider on stopping the infusion during a suspected allergic reaction applies; let the emergency team or your prescriber advise on next steps and whether treatment can be resumed.
Are there any long-term risks with Wilate?
Long-term risks include the potential development of inhibitors (antibodies) to factor VIII or VWF, and a very small risk of transmitting infectious agents.
Can I self-administer Wilate at home?
Yes, with proper training from your healthcare provider, you may be able to self-administer Wilate at home.
What should I do if I miss a dose of Wilate?
Contact your healthcare provider for instructions. Do not take an extra dose to make up for a missed one.
What happens if I take too much Wilate?
Taking too much Wilate may increase the risk of thrombotic events due to elevated clotting factor levels. Symptoms could include chest pain, shortness of breath, or swelling in the limbs. If you suspect an overdose, seek immediate emergency medical attention. Your healthcare provider will monitor your coagulation parameters and provide appropriate supportive care.
Can I drink alcohol while taking Wilate?
While there are no specific known direct interactions between Wilate and alcohol, it is generally advisable to limit or avoid alcohol consumption. Alcohol can impair liver function, which plays a crucial role in coagulation. Additionally, excessive alcohol intake can increase the risk of bleeding, potentially counteracting the therapeutic effects of Wilate. Always consult your healthcare provider for personalized advice.
Is Wilate safe during pregnancy?
The safety of Wilate during pregnancy has not been definitively established. It is categorized as 'Consult doctor' regarding pregnancy. If you are pregnant, planning to become pregnant, or breastfeeding, it is crucial to discuss the potential risks and benefits with your healthcare provider. They will assess your individual situation and determine the most appropriate course of treatment.
What is the mechanism of action of von Willebrand factor and coagulation factor VIII (human)?
Wilate provides exogenous von Willebrand factor (VWF) and coagulation factor VIII (FVIII), both derived from human plasma. VWF mediates platelet adhesion to sites of vascular injury and stabilizes circulating FVIII, which is essential for the intrinsic pathway of blood coagulation. By replacing deficient or dysfunctional VWF and FVIII, Wilate restores hemostasis in patients with von Willebrand disease and hemophilia A. (1)
What is the generic name of Von Willebrand Factor And Coagulation Factor VIII (Human)?
The generic name is von Willebrand factor and coagulation factor VIII (human). It is sold under brand names including VWF8, FactorWil, Wilate.
What class of drug is von Willebrand factor and coagulation factor VIII (human)?
Von Willebrand Factor And Coagulation Factor VIII (Human) is classed as: Cardiovascular & Circulatory System.
References
- Wilate — Prescribing InformationDailyMed, U.S. National Library of Medicine · United States · accessed 2026-08-03 · source 1
Brand names by country
Single-ingredient von Willebrand factor and coagulation factor VIII (human) names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United Kingdom
- Wilate 500, 500 IU VWF/500 IU FVIII, powder and solvent for solution for injection500 IU VWF / 500 IU FVIII · Octapharma Limited
- Wilate 1000, 1000 IU VWF/1000 IU FVIII, powder and solvent for solution for injection1000 IU VWF / 1000 IU FVIII · Octapharma Limited
- Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion500 IU FVIII / 1200 IU VWF · CSL Behring UK Limited
- Voncento 1000 IU FVIII / 2400 IU VWF (10 ml solvent) powder and solvent for solution for injection/infusion1000 IU FVIII / 2400 IU VWF · CSL Behring UK Limited
- Optivate 100 IU/ml powder and solvent for solution for injection100 IU/ml · Bio Products Laboratory Limited
- Octanate LV 100 IU/ml powder and solvent for solution for injection100 IU/ml · Octapharma Limited
- Dried Factor VIII Fraction Type 8Y 25 IU/ml powder for solution for injection25 IU/ml · Bio Products Laboratory Limited